Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.48 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440360 | 0.99 | FAAH (0.53) | FAAHDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL16826134 | 0.99 | FAAH (0.53) | FAAHDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL23475720 | 0.94 | FAAH (0.48) | FAAHDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL31493605 | 0.92 | DGKA (0.56) | FAAHDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL22694956 | 0.92 | FAAH (0.48) | FAAHDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL23453828 | 0.91 | FAAH (0.52) | FAAHDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL23475745 | 0.90 | FAAH (0.52) | FAAHDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL21599260 | 0.89 | FAAH (0.44) | FAAHDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL23475708 | 0.88 | FAAH (0.44) | FAAHDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL23475704 | 0.88 | FAAH (0.43) | FAAHDGKAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223285-A2 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | Novartis AG (CH) | 2023-08-09 | — | — | EP | claimed |
| EP-3083556-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-12-25 | — | — | EP | claimed |
| US-10059655-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-08-28 | — | — | US | claimed |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | NOVARTIS AG (CH) | 2019-07-09 | — | — | US | disclosed |
| US-20180290965-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-10-11 | — | — | US | disclosed |
| US-10059655-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-08-28 | — | — | US | disclosed |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-07-13 | — | — | US | disclosed |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| WO-2015095340-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | FAAH 1206/4885DGKA 458/4885PRKCE 4209/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | FAAH 2030/4885DGKA 1366/4885PRKCE 2833/4885 |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | POLN, POLRMT, RNGTT | FAAH 1443/4885DGKA 987/4885PRKCE 3602/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | FAAH 3070/4885DGKA 474/4885PRKCE 3225/4885 |
| US-20180290965-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LPAR1, LPAR4, LIPA | FAAH 1574/4885DGKA 2105/4885PRKCE 3612/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | FAAH 2196/4885DGKA 2356/4885PRKCE 2260/4885 |
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | POLN, POLRMT, RNGTT | FAAH 1443/4885DGKA 987/4885PRKCE 3602/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | FAAH 1206/4885DGKA 458/4885PRKCE 4209/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | FAAH 2169/4885DGKA 516/4885PRKCE 3279/4885 |
| US-10059655-B2 | Lipids and lipid compositions for the delivery of active agents | PHOSPHO1, SGMS1, ABCB4 | FAAH 1462/4885DGKA 1366/4885PRKCE 2970/4885 |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | FAAH 2169/4885DGKA 516/4885PRKCE 3279/4885 |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | NSUN3, PHAX, RNGTT | FAAH 4068/4885DGKA 2535/4885PRKCE 4490/4885 |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | PHOSPHO1, SGMS1, ABCB4 | FAAH 1462/4885DGKA 1366/4885PRKCE 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.